On the other hand, calretinin was an important predictive biomarker in MM patients treated with cisplatin-based chemotherapy, even in multivariable analysis: serum calretinin concentration was significantly higher in patients who had disease progression during or after the completion of chemotherapy and was associated with worse PFS and OS. The gene discussed is CALB2; the disease is Miyoshi myopathy.